Xeloda (Capecitabine)

Brand Options

arrow pointer

Brand Name : Xeloda

Marketing Authorization Holder : Roche

Prescription Required

 
 

Generic Option

arrow pointer2

Generic Name : Capecitabine

Manufactured By : Authorized UK Generic

Prescription Required

 
 

Product Details

Xeloda

Information about Xeloda (Capecitabine)

Xeloda contains capecitabine, which is an oral prodrug that gets converted into 5-fluorouracil (5-FU) in the body. 5-FU is an anti-metabolite chemotherapy drug that works by inhibiting the growth of cancer cells. It is commonly used to treat breast cancer, colon cancer, and other solid tumors.

Product Highlights

  • Xeloda is used to treat both early-stage and metastatic breast cancer, often after surgery or in combination with other therapies.
  • Xeloda is indicated for the adjuvant treatment of colon cancer following surgery and also for metastatic colon cancer.
  • It may be used in combination with other chemotherapy drugs for the treatment of metastatic or locally advanced rectal cancer.
  • Xeloda is also utilized in the treatment of other cancers, such as gastric cancer and pancreatic cancer, in certain cases as part of a combination therapy.

Key Ingredient

  • Capecitabine

Key Benefits

  • Xeloda is taken orally, making it more convenient for patients compared to intravenous chemotherapy treatments.
  • It is effective in treating a range of cancers, especially breast and colon cancer.
  • Xeloda is converted into its active form in cancer cells, offering a more targeted approach that may reduce damage to healthy cells compared to traditional chemotherapy.
  • It can be combined with other chemotherapy agents to improve the efficacy of treatment in certain cancers.

Direction of Use

  • Xeloda is typically taken twice daily for two weeks, followed by a one-week rest period, but this can vary based on your doctor's instructions. The dose is individualized according to the type of cancer being treated and the patient's response.
  • The tablet should be taken with food, typically within 30 minutes after a meal to reduce gastrointestinal side effects.
  • If you forget a dose, take it as soon as you can, unless it's nearly time for your next dose. Do not take an extra dose to compensate for the missed one. 
  • Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Safety Concerns

  • Common side effects include nausea, vomiting, diarrhea, hand-foot syndrome (pain, redness, and swelling of the palms and soles), and fatigue. Serious side effects may include heart problems, liver toxicity, and severe gastrointestinal issues.
  • Capecitabine can cause bone marrow suppression, leading to a decrease in blood cell counts. Regular blood tests are required to monitor blood cell levels.
  • Liver function may be affected by Xeloda, so periodic liver function tests are necessary.
  • Xeloda should be avoided during pregnancy and breastfeeding as it can cause harm to a developing fetus or infant.
  • Xeloda may interact with certain medications, including anticoagulants, and may increase the risk of bleeding. Make sure to tell your doctor about any other medications you are currently taking. 
  • This condition, which causes redness, swelling, and pain in the hands and feet, is a known side effect of Xeloda and may require dose adjustments.

Avoid Xeloda (Capecitabine) If

  • Xeloda should not be used during pregnancy or while breastfeeding due to potential risks to the fetus or infant.
  • Avoid Xeloda if you have severe liver impairment or active liver disease.
  • Xeloda should be avoided in patients with severe kidney problems, as the drug is metabolized and excreted by the kidneys.
  • Do not take Xeloda if you have had a severe allergic reaction to capecitabine or any of its components.
  • If you have a history of bone marrow suppression or low blood cell counts, you may need to avoid or use Xeloda with caution.
  • Xeloda should be avoided or closely monitored in patients with severe diarrhea or dehydration, as it may worsen these conditions.


Image Image Image Image